|
CA2344246A1
(en)
*
|
1998-09-17 |
2000-03-23 |
Akesis Pharmaceuticals, Inc. |
Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
|
|
US6376549B1
(en)
*
|
1998-09-17 |
2002-04-23 |
Akesis Pharmaceuticals, Inc. |
Metforimin-containing compositions for the treatment of diabetes
|
|
DE19940130A1
(de)
*
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
|
JP2003535034A
(ja)
*
|
1999-11-12 |
2003-11-25 |
ギルフォード ファーマシューティカルズ インコーポレイテッド |
ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
|
|
US20040152745A1
(en)
*
|
1999-11-12 |
2004-08-05 |
Guilford Pharmaceuticals, Inc. |
Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
|
|
GB9928330D0
(en)
*
|
1999-11-30 |
2000-01-26 |
Ferring Bv |
Novel antidiabetic agents
|
|
JP2003518496A
(ja)
*
|
1999-12-23 |
2003-06-10 |
ノバルティス アクチエンゲゼルシャフト |
グルコース代謝障害を処置するための血糖降下薬の使用
|
|
US6380398B2
(en)
|
2000-01-04 |
2002-04-30 |
Novo Nordisk A/S |
Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
|
US20080076811A1
(en)
*
|
2000-01-21 |
2008-03-27 |
Bork Balkan |
Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
|
|
EP1741445B1
(en)
|
2000-01-21 |
2013-08-14 |
Novartis AG |
Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
|
|
WO2001055105A1
(en)
*
|
2000-01-24 |
2001-08-02 |
Novo Nordisk A/S |
N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
|
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
|
US6432969B1
(en)
|
2000-06-13 |
2002-08-13 |
Novartis Ag |
N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
|
HUP0301622A3
(en)
|
2000-07-04 |
2006-05-29 |
Novo Nordisk As |
Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
|
|
PE20020617A1
(es)
*
|
2000-08-22 |
2002-08-05 |
Novartis Ag |
Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
|
|
US20060089389A1
(en)
*
|
2000-08-22 |
2006-04-27 |
Malcolm Allison |
Combination
|
|
US20080249016A1
(en)
*
|
2000-09-18 |
2008-10-09 |
Sanos Bioscience A/S |
Use of GLP-2 in a combination treatment for bone-related disorders
|
|
US7371721B2
(en)
*
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
|
PT1326630E
(pt)
|
2000-09-18 |
2008-09-02 |
Sanos Bioscience As |
Utilização de péptidos glp-2
|
|
US20070135345A1
(en)
*
|
2000-09-18 |
2007-06-14 |
Henriksen Dennis B |
Use of GLP-2 for the treatment or prevention, of bone-related disorders
|
|
DE60135764D1
(de)
|
2000-10-06 |
2008-10-23 |
Mitsubishi Tanabe Pharma Corp |
Stickstoffhaltige, fünfgliedrige ringverbindungen
|
|
TWI243162B
(en)
*
|
2000-11-10 |
2005-11-11 |
Taisho Pharmaceutical Co Ltd |
Cyanopyrrolidine derivatives
|
|
UA74023C2
(en)
*
|
2000-11-10 |
2005-10-17 |
Taisho Pharmaceutical Co Ltd |
Cyanopyrrolidine derivatives
|
|
JPWO2002051836A1
(ja)
*
|
2000-12-27 |
2004-04-22 |
協和醗酵工業株式会社 |
ジペプチジルペプチダーゼ−ｉｖ阻害剤
|
|
GB0109146D0
(en)
*
|
2001-04-11 |
2001-05-30 |
Ferring Bv |
Treatment of type 2 diabetes
|
|
US20030060494A1
(en)
*
|
2001-05-18 |
2003-03-27 |
Nobuyuki Yasuda |
Pharmaceutical use of N-carbamoylazole derivatives
|
|
WO2003000180A2
(en)
|
2001-06-20 |
2003-01-03 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
|
AU2002310465B2
(en)
|
2001-06-20 |
2006-06-15 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
|
WO2003002553A2
(en)
*
|
2001-06-27 |
2003-01-09 |
Smithkline Beecham Corporation |
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
|
|
AU2002322344C1
(en)
*
|
2001-06-27 |
2006-02-16 |
Smithkline Beecham Corporation |
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
|
|
DE60223920T2
(de)
|
2001-06-27 |
2008-11-13 |
Smithkline Beecham Corp. |
Pyrrolidine als dipeptidyl-peptidase-inhibitoren
|
|
US6709651B2
(en)
*
|
2001-07-03 |
2004-03-23 |
B.M.R.A. Corporation B.V. |
Treatment of substance P-related disorders
|
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
|
WO2003038123A2
(en)
*
|
2001-10-31 |
2003-05-08 |
Novartis Ag |
Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
|
|
US20050101638A1
(en)
*
|
2002-11-08 |
2005-05-12 |
Webb Randy L. |
Combination of organic compounds
|
|
US20030135663A1
(en)
*
|
2002-01-16 |
2003-07-17 |
Sun Microsystems, Inc. |
Method, system, and program for including device parameters from a device driver in a configuration file
|
|
CA2474460C
(en)
|
2002-02-13 |
2009-12-22 |
F. Hoffmann-La Roche Ag |
Pyridine- and quinoline-derivatives
|
|
KR100608414B1
(ko)
|
2002-02-13 |
2006-08-02 |
에프. 호프만-라 로슈 아게 |
신규한 피리딘- 및 피리미딘-유도체
|
|
EP1338595B1
(en)
|
2002-02-25 |
2006-05-03 |
Eisai Co., Ltd. |
Xanthine derivatives as DPP-IV inhibitors
|
|
ATE373660T1
(de)
*
|
2002-03-25 |
2007-10-15 |
Merck & Co Inc |
Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
|
|
KR20050012771A
(ko)
*
|
2002-06-03 |
2005-02-02 |
노파르티스 아게 |
치환된 시아노피롤리딘의 용도 및 이들을 함유하는고지혈증 및 관련 질환의 치료를 위한 조합 제제
|
|
US6710040B1
(en)
*
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
|
JP2004026678A
(ja)
*
|
2002-06-24 |
2004-01-29 |
Microbial Chem Res Found |
２型糖尿病治療剤
|
|
JPWO2004007446A1
(ja)
*
|
2002-07-10 |
2005-11-10 |
アステラス製薬株式会社 |
新規なアゼチジン誘導体又はその塩
|
|
US7208498B2
(en)
*
|
2002-07-15 |
2007-04-24 |
Merck & Co., Inc. |
Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
|
|
TW200401635A
(en)
*
|
2002-07-23 |
2004-02-01 |
Yamanouchi Pharma Co Ltd |
2-Cyano-4-fluoropyrrolidine derivative or salt thereof
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
PT1560811E
(pt)
*
|
2002-09-19 |
2007-11-14 |
Abbott Lab |
Composições farmacêuticas como inibidores de dipeptidilpeptidase-iv ( dpp-iv)
|
|
DE60315687T2
(de)
*
|
2002-10-07 |
2008-06-05 |
Merck & Co., Inc. |
Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase
|
|
ES2301879T3
(es)
|
2002-10-18 |
2008-07-01 |
MERCK & CO., INC. |
Inhibidores de dipeptidilpeptidasa heterociclica beta-amino para el tratamiento o prevencion de diabetes.
|
|
PL376822A1
(pl)
|
2002-11-07 |
2006-01-09 |
Merck & Co., Inc. |
Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy
|
|
US7309714B2
(en)
*
|
2002-12-04 |
2007-12-18 |
Merck & Co., Inc. |
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
CA2508947A1
(en)
*
|
2002-12-20 |
2004-07-15 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
CN102558155A
(zh)
|
2003-01-14 |
2012-07-11 |
阿伦纳药品公司 |
作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
|
|
CA2512546A1
(en)
|
2003-01-17 |
2004-08-05 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
AU2004210149A1
(en)
*
|
2003-01-31 |
2004-08-19 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
US7550590B2
(en)
|
2003-03-25 |
2009-06-23 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
PE20050021A1
(es)
|
2003-04-16 |
2005-03-15 |
Novartis Ag |
Procedimiento para la preparacion de 2-cianopirrolidina n-sustituida
|
|
GB0308854D0
(en)
*
|
2003-04-16 |
2003-05-21 |
Novartis Ag |
Organic compounds
|
|
CA2524531A1
(en)
*
|
2003-05-14 |
2004-12-02 |
Merck And Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
EP1625122A1
(en)
|
2003-05-14 |
2006-02-15 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
CA2526770A1
(en)
|
2003-06-06 |
2004-12-23 |
Merck & Co., Inc. |
Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
AU2004249163A1
(en)
*
|
2003-06-17 |
2004-12-29 |
Merck & Co., Inc. |
Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
EP1638968B1
(en)
|
2003-06-20 |
2009-07-29 |
F.Hoffmann-La Roche Ag |
Hexahydropyridoisoqinolines as dpp-iv inhibitors
|
|
RS52397B
(sr)
|
2003-06-20 |
2013-02-28 |
F.Hoffmann-La Roche Ag |
Derivati pirido /2,1-a/izohinolina kao dpp-iv inhibitori
|
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
EP1651623B1
(en)
|
2003-07-31 |
2008-12-17 |
Merck & Co., Inc. |
Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US20050070531A1
(en)
|
2003-08-13 |
2005-03-31 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
|
JP2007505121A
(ja)
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
|
PE20050948A1
(es)
*
|
2003-09-09 |
2005-12-16 |
Japan Tobacco Inc |
Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
|
|
WO2005033099A2
(en)
*
|
2003-10-03 |
2005-04-14 |
Glenmark Pharmaceuticals Ltd. |
Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
|
|
ZA200603165B
(en)
*
|
2003-11-03 |
2007-07-25 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
|
JP2007510651A
(ja)
*
|
2003-11-04 |
2007-04-26 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合フェニルアラニン誘導体
|
|
US7317109B2
(en)
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
WO2005047297A1
(en)
*
|
2003-11-12 |
2005-05-26 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
RU2385723C2
(ru)
*
|
2003-11-17 |
2010-04-10 |
Новартис Аг |
Применение ингибиторов дипептидилпептидазы iv
|
|
CA2545641A1
(en)
*
|
2003-11-17 |
2005-06-02 |
Novartis Ag |
Use of organic compounds
|
|
BRPI0507007A
(pt)
|
2004-01-20 |
2007-06-05 |
Novartis Ag |
formulação e processo de compressão direta
|
|
ES2375625T3
(es)
*
|
2004-02-05 |
2012-03-02 |
Kyorin Pharmaceutical Co., Ltd. |
Derivados de biciclo éster.
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
EP1717225A4
(en)
*
|
2004-02-18 |
2009-10-21 |
Kyorin Seiyaku Kk |
BICYCLIC AMID DERIVATIVES
|
|
US20090017015A1
(en)
*
|
2004-02-20 |
2009-01-15 |
Thomas Edward Hughes |
Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
|
|
WO2005082847A1
(ja)
*
|
2004-02-27 |
2005-09-09 |
Kyorin Pharmaceutical Co., Ltd. |
ビシクロ誘導体
|
|
US7687504B2
(en)
*
|
2004-03-09 |
2010-03-30 |
National Health Research Institutes |
Pyrrolidine compounds
|
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
GEP20094679B
(en)
|
2004-03-15 |
2009-05-10 |
Takeda Pharmaceuticals Co |
Dipeptidyl peptidase inhibitors
|
|
US7741082B2
(en)
*
|
2004-04-14 |
2010-06-22 |
Bristol-Myers Squibb Company |
Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
|
|
TW200604167A
(en)
*
|
2004-04-27 |
2006-02-01 |
Astellas Pharma Inc |
Pyrrolidine derivatives
|
|
JP2007536234A
(ja)
|
2004-05-04 |
2007-12-13 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての１，２，４−オキサジアゾール誘導体
|
|
CA2564884A1
(en)
*
|
2004-05-18 |
2005-12-08 |
Merck & Co., Inc. |
Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
US7687638B2
(en)
|
2004-06-04 |
2010-03-30 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
US7935723B2
(en)
*
|
2004-06-04 |
2011-05-03 |
Novartis Pharma Ag |
Use of organic compounds
|
|
US7786163B2
(en)
|
2004-07-12 |
2010-08-31 |
Forest Laboratories Holdings Limited (BM) |
Constrained cyano compounds
|
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
ATE553077T1
(de)
|
2004-07-23 |
2012-04-15 |
Nuada Llc |
Peptidaseinhibitoren
|
|
TW200608967A
(en)
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
|
AR050615A1
(es)
*
|
2004-08-27 |
2006-11-08 |
Novartis Ag |
Composiciones farmaceuticas para la administracion oral
|
|
WO2006040625A1
(en)
|
2004-10-12 |
2006-04-20 |
Glenmark Pharmaceuticals S.A. |
Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation
|
|
WO2006047248A1
(en)
*
|
2004-10-25 |
2006-05-04 |
Novartis Ag |
Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
US7411093B2
(en)
|
2004-12-20 |
2008-08-12 |
Hoffman-La Roche Inc. |
Aminocycloalkanes as DPP-IV inhibitors
|
|
CN101090888A
(zh)
|
2004-12-20 |
2007-12-19 |
霍夫曼-拉罗奇有限公司 |
4－氨基哌啶衍生物
|
|
EP1828192B1
(en)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
|
GT200600008A
(es)
*
|
2005-01-18 |
2006-08-09 |
|
Formulacion de compresion directa y proceso
|
|
JP2008024592A
(ja)
*
|
2005-01-28 |
2008-02-07 |
Taisho Pharmaceut Co Ltd |
シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
|
|
WO2006090244A1
(en)
*
|
2005-02-22 |
2006-08-31 |
Glenmark Pharmaceuticals S.A. |
New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them
|
|
TWI357902B
(en)
|
2005-04-01 |
2012-02-11 |
Lg Life Science Ltd |
Dipeptidyl peptidase-iv inhibiting compounds, meth
|
|
MX2007011453A
(es)
|
2005-04-22 |
2008-02-12 |
Alantos Pharmaceuticals Holding Inc |
Inhibidores de la dipeptidil peptidasa-iv.
|
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
WO2006133160A2
(en)
|
2005-06-06 |
2006-12-14 |
Georgetown University |
Compositions and methods for lipo modeling
|
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
|
WO2006134613A2
(en)
*
|
2005-06-17 |
2006-12-21 |
Aurigene Discovery Technologies Limited |
Novel 5-substituted indole derivatives as dipeptidyl peptidase iv (dpp-iv) inhibitors
|
|
AU2006268650A1
(en)
*
|
2005-07-12 |
2007-01-18 |
Novartis Ag |
Combination of a DPP-IV inhibitor and a cannabinoid CB1 receptor antagonist
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
US20080279932A1
(en)
*
|
2005-08-04 |
2008-11-13 |
Jean-Louis Reber |
Compounds
|
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
|
US20070060530A1
(en)
|
2005-09-14 |
2007-03-15 |
Christopher Ronald J |
Administration of dipeptidyl peptidase inhibitors
|
|
EP1924567B1
(en)
|
2005-09-16 |
2012-08-22 |
Takeda Pharmaceutical Company Limited |
Process for the preparation of pyrimidinedione derivatives
|
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
|
JOP20180109A1
(ar)
*
|
2005-09-29 |
2019-01-30 |
Novartis Ag |
تركيبة جديدة
|
|
US20100144613A1
(en)
*
|
2005-10-07 |
2010-06-10 |
Antonio Cruz |
Combined use of DPP-IV Inhibitors and Gastrin Compounds
|
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
|
CA2635399A1
(en)
*
|
2006-01-06 |
2007-10-25 |
Novartis Ag |
Use.of vildagliptin for the treatment of diabetes
|
|
CA2645154C
(en)
*
|
2006-03-08 |
2011-11-29 |
Kyorin Pharmaceutical Co., Ltd. |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
|
|
AU2007227202B2
(en)
|
2006-03-21 |
2013-08-22 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase inhibitor conjugates and methods of using same
|
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
MX2008012756A
(es)
*
|
2006-04-03 |
2009-03-05 |
Matrix Lab Ltd |
Inhibidores de dipeptidil peptidasa iv novedosos y procesos para su preparacion y composiciones farmaceuticas que los contienen.
|
|
BRPI0709894A2
(pt)
*
|
2006-04-03 |
2011-07-26 |
Matrix Lab Ltd |
inibidores de dipeptidil peptidase iv e processos para sua preparaÇço e composiÇço farmacÊuticas contendo-os
|
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
CN103536924A
(zh)
|
2006-04-11 |
2014-01-29 |
艾尼纳制药公司 |
使用gpr119受体鉴定可用于增加个体骨质量的化合物的方法
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
KR101541791B1
(ko)
|
2006-05-04 |
2015-08-04 |
베링거 인겔하임 인터내셔날 게엠베하 |
다형태
|
|
CN101454342A
(zh)
|
2006-05-26 |
2009-06-10 |
安米林药品公司 |
用于治疗充血性心力衰竭的组合物及方法
|
|
AU2007293885A1
(en)
|
2006-09-07 |
2008-03-13 |
Takeda Gmbh |
Combination treatment for diabetes mellitus
|
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
|
KR102062824B1
(ko)
*
|
2006-09-13 |
2020-01-07 |
다케다 야쿠힌 고교 가부시키가이샤 |
2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
|
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
WO2008084383A2
(en)
*
|
2007-01-10 |
2008-07-17 |
Medichem, S.A. |
Process for preparing vildagliptin
|
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
|
JPWO2008114857A1
(ja)
|
2007-03-22 |
2010-07-08 |
杏林製薬株式会社 |
アミノアセチルピロリジンカルボニトリル誘導体の製造方法
|
|
CN103330939A
(zh)
|
2007-04-03 |
2013-10-02 |
田边三菱制药株式会社 |
二肽基肽酶iv抑制化合物和甜味剂的并用
|
|
DE102007022007A1
(de)
*
|
2007-05-08 |
2008-11-13 |
Schebo Biotech Ag |
Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes
|
|
KR101560844B1
(ko)
|
2007-06-04 |
2015-10-15 |
벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 |
트라이-아릴계 화합물 및 이를 포함하는 조성물
|
|
CL2008002427A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
|
AU2008290582B2
(en)
*
|
2007-08-17 |
2014-08-14 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
|
WO2009037719A1
(en)
*
|
2007-09-21 |
2009-03-26 |
Lupin Limited |
Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
|
|
US20090082420A1
(en)
*
|
2007-09-25 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched vildagliptin
|
|
WO2009042922A2
(en)
*
|
2007-09-27 |
2009-04-02 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of making and using same
|
|
CA2704493A1
(en)
*
|
2007-11-30 |
2009-06-04 |
Novartis Ag |
Organic compounds
|
|
JP2011506421A
(ja)
*
|
2007-12-12 |
2011-03-03 |
アストラゼネカ・アクチエボラーグ |
ペプチジルニトリル類およびジペプチジルペプチダーゼｉ阻害剤としてのその使用
|
|
UA103181C2
(ru)
|
2007-12-21 |
2013-09-25 |
Ел Джи Лайф Сайєнсіз, Лтд. |
Соединения, которые ингибируют дипептидилпептидазу-iv и фармацевтическая композиция, которая содержит их как активный агент
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
|
PE20140960A1
(es)
*
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
EP2108960A1
(en)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
|
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
|
WO2009155309A1
(en)
*
|
2008-06-19 |
2009-12-23 |
Concert Pharmaceuticals, Inc. |
Substituted cyanopyrrolidine derivatives
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
US8476470B2
(en)
*
|
2008-08-07 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Process for production of bicyclo[2.2.2]octylamine derivative
|
|
CA2733778A1
(en)
*
|
2008-08-14 |
2010-02-18 |
Hiroshi Uchida |
Stabilized pharmaceutical composition
|
|
US20110190322A1
(en)
|
2008-08-14 |
2011-08-04 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
|
CZ2008512A3
(cs)
|
2008-08-26 |
2010-03-10 |
Zentiva, A. S |
Zpusob prípravy vysoce cistého vildagliptinu
|
|
BRPI0919288A2
(pt)
|
2008-09-10 |
2015-12-15 |
Boehring Ingelheim Internat Gmbh |
teriapia de combinação para tratamento de diabetes e condições relacionadas.
|
|
CN102850330B
(zh)
*
|
2008-09-23 |
2014-10-15 |
成都地奥制药集团有限公司 |
经溴代的制备n取代的吡咯烷衍生物的方法
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
|
KR20110103968A
(ko)
|
2008-12-23 |
2011-09-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
유기 화합물의 염 형태
|
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
|
AU2010204144B2
(en)
|
2009-01-09 |
2012-02-16 |
Orchid Research Laboratories Ltd. |
Dipeptidyl peptidase IV inhibitors
|
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
|
MY160123A
(en)
|
2009-02-13 |
2017-02-28 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
|
NZ594044A
(en)
|
2009-02-13 |
2014-08-29 |
Boehringer Ingelheim Int |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
|
US20120029032A1
(en)
|
2009-03-27 |
2012-02-02 |
Kyorin Pharmaceutical Co., Ltd. |
Matrix-type sustained release preparation containing basic additive
|
|
EA201190235A1
(ru)
|
2009-05-07 |
2012-05-30 |
Астразенека Аб |
Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
|
|
SG175925A1
(en)
|
2009-05-15 |
2011-12-29 |
Novartis Ag |
Aryl pyridine as aldosterone synthase inhibitors
|
|
EA201101621A1
(ru)
|
2009-05-15 |
2012-05-30 |
Новартис Аг |
Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
|
|
EA201101672A1
(ru)
|
2009-05-28 |
2012-06-29 |
Новартис Аг |
Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
|
|
SI2435409T1
(sl)
|
2009-05-28 |
2014-12-31 |
Novartis Ag |
Substituirani aminopropionski derivati kot inhibitorji neprilizina
|
|
WO2010146597A1
(en)
|
2009-06-18 |
2010-12-23 |
Lupin Limited |
2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
|
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
WO2011012322A2
(en)
|
2009-07-31 |
2011-02-03 |
Krka, D.D., Novo Mesto |
Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms
|
|
BR112012004335A8
(pt)
|
2009-09-02 |
2016-06-21 |
Merck Sharp & Dohme |
Composto, composição farmacêutica, e, uso do composto.
|
|
HUE024874T2
(en)
|
2009-09-03 |
2016-02-29 |
Bioenergenix |
Heterocyclic compounds for the inhibition of pask
|
|
CA2939165A1
(en)
|
2009-09-15 |
2011-03-24 |
Cerulean Pharma Inc. |
A cdp-camptothecin conjugate, particle or composition and uses thereof
|
|
EP2295083A1
(de)
|
2009-09-15 |
2011-03-16 |
Ratiopharm GmbH |
Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
|
|
HUP0900638A2
(en)
|
2009-10-07 |
2011-05-30 |
Egyt Gyogyszervegyeszeti Gyar |
Adducts of inorganic salts basea on vildaelitpin applicable for preparation of pharmaceutical compositions
|
|
EP2308847B1
(en)
|
2009-10-09 |
2014-04-02 |
EMC microcollections GmbH |
Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
|
|
IN2012DN02471A
(cg-RX-API-DMAC10.html)
|
2009-10-09 |
2015-08-21 |
Irm Llc |
|
|
WO2011061168A1
(en)
|
2009-11-17 |
2011-05-26 |
Novartis Ag |
Aryl-pyridine derivatives as aldosterone synthase inhibitors
|
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
|
EA201200617A1
(ru)
|
2009-11-23 |
2012-11-30 |
Серулин Фарма Инк. |
Полимеры на основе циклодекстрина для доставки лекарственных средств
|
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
|
US8575160B2
(en)
|
2009-11-30 |
2013-11-05 |
Novartis Ag |
Imidazole derivatives as aldosterone synthase inhibitors
|
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
|
US8796468B2
(en)
|
2009-12-22 |
2014-08-05 |
Shionogi & Co., Ltd. |
Adamantanamine derivative
|
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
|
WO2011103256A1
(en)
|
2010-02-22 |
2011-08-25 |
Merck Sharp & Dohme Corp. |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
|
CN101798270B
(zh)
*
|
2010-02-25 |
2013-04-17 |
东华大学 |
一种3-氨基-1-金刚烷醇的制备方法
|
|
WO2011113947A1
(en)
|
2010-03-18 |
2011-09-22 |
Boehringer Ingelheim International Gmbh |
Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
|
AU2011237775A1
(en)
|
2010-04-06 |
2012-11-22 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
|
ES2935300T3
(es)
|
2010-05-05 |
2023-03-03 |
Boehringer Ingelheim Int |
Combiterapia
|
|
WO2011146358A1
(en)
|
2010-05-21 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
|
CN102260265B
(zh)
|
2010-05-24 |
2015-09-02 |
上海阳帆医药科技有限公司 |
六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
|
|
CN101870671B
(zh)
*
|
2010-06-11 |
2012-06-27 |
漆又毛 |
金刚烷基吡咯烷衍生物及制备和应用
|
|
MX2012014247A
(es)
|
2010-06-24 |
2013-01-18 |
Boehringer Ingelheim Int |
Terapia para la diabetes.
|
|
IT1400714B1
(it)
|
2010-07-06 |
2013-06-28 |
Chemelectiva S R L |
Processo ed intermedi per la preparazione di un principio attivo.
|
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
|
CN103209957A
(zh)
*
|
2010-08-09 |
2013-07-17 |
盐野义制药株式会社 |
氨基金刚烷氨基甲酸酯衍生物的制备方法
|
|
HU231050B1
(hu)
|
2010-08-19 |
2020-02-28 |
Egis Gyógyszergyár Nyrt. |
Eljárás gyógyszerhatóanyag előállítására
|
|
EA201390421A1
(ru)
|
2010-09-22 |
2013-09-30 |
Арена Фармасьютикалз, Инк. |
Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
|
EP2468268B1
(en)
|
2010-12-21 |
2017-12-13 |
Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi |
Combination composition of vildagliptin and gliclazide
|
|
TR201010683A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç San. Ve Ti̇c. A.Ş. |
Vildagliptin formülasyonları.
|
|
TR201101809A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ |
Vildagliptin ve glimepirid kombinasyonları.
|
|
TR201107482A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç San.Ve Ti̇c.A.Ş. |
Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
|
|
HUE027512T2
(en)
|
2011-01-31 |
2016-10-28 |
Cadila Healthcare Ltd |
Treatment for lipodystrophy
|
|
WO2012119046A2
(en)
|
2011-03-02 |
2012-09-07 |
Bioenergenix |
Heterocyclic compounds for the inhibition of pask
|
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
US20140038889A1
(en)
|
2011-04-22 |
2014-02-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
|
WO2012145604A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
US9051329B2
(en)
|
2011-07-05 |
2015-06-09 |
Merck Sharp & Dohme Corp. |
Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
|
|
ES2934843T3
(es)
|
2011-07-15 |
2023-02-27 |
Boehringer Ingelheim Int |
Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
|
|
US20140302150A1
(en)
|
2011-09-07 |
2014-10-09 |
Umit Cifter |
Dpp-iv inhibitor formulations
|
|
EP2572704A1
(en)
|
2011-09-22 |
2013-03-27 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Orally-Disintegrating Formulations of Vildagliptin
|
|
ES2487271T3
(es)
|
2011-10-06 |
2014-08-20 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Formulaciones de dosificación sólidas inhibidoras de DPP-IV
|
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
ITMI20112224A1
(it)
|
2011-12-06 |
2013-06-07 |
Chemelectiva S R L |
Nuovo processo ed intermedi per la sintesi di vildagliptin
|
|
CN102491928A
(zh)
*
|
2011-12-13 |
2012-06-13 |
临海天宇药业有限公司 |
一种制备(2s)-n-氯乙酰基-2-氰基四氢吡咯的方法
|
|
US9115082B2
(en)
|
2012-01-18 |
2015-08-25 |
Catherine Yang |
Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
|
|
WO2013122920A1
(en)
|
2012-02-17 |
2013-08-22 |
Merck Sharp & Dohme Corp. |
Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
CN102617434B
(zh)
*
|
2012-03-29 |
2014-07-23 |
中国科学院上海有机化学研究所 |
一锅法制备维达列汀
|
|
IN2012MU01383A
(cg-RX-API-DMAC10.html)
*
|
2012-05-04 |
2014-02-28 |
|
|
|
US20130303462A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
|
|
EP4151218A1
(en)
|
2012-05-14 |
2023-03-22 |
Boehringer Ingelheim International GmbH |
Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
EP2874622A4
(en)
|
2012-07-23 |
2015-12-30 |
Merck Sharp & Dohme |
TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
|
|
WO2014020462A1
(en)
*
|
2012-08-01 |
2014-02-06 |
Alembic Pharmaceuticals Limited |
Improved process for preparation of vildagliptin intermediate
|
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
|
TWI500613B
(zh)
|
2012-10-17 |
2015-09-21 |
Cadila Healthcare Ltd |
新穎之雜環化合物
|
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
|
CN103922986B
(zh)
*
|
2013-01-16 |
2017-02-15 |
上海彩迩文生化科技有限公司 |
维大列汀及其类似物、中间体及其制备方法和应用
|
|
JP6295277B2
(ja)
|
2013-02-14 |
2018-03-14 |
ノバルティス アーゲー |
Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
|
|
GEP201706663B
(en)
|
2013-04-22 |
2017-05-10 |
Cadila Healthcare Ltd |
Novel composition for nonalcoholic fatty liver disease (nafld
|
|
MX2015016403A
(es)
|
2013-05-30 |
2016-04-11 |
Cadila Healthcare Ltd |
Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
|
|
CN103304502B
(zh)
*
|
2013-06-02 |
2015-03-04 |
张远强 |
一类抗糖尿病化合物、其制备方法和用途
|
|
TW201513857A
(zh)
|
2013-07-05 |
2015-04-16 |
Cadila Healthcare Ltd |
協同性組成物
|
|
JP2016527249A
(ja)
|
2013-07-25 |
2016-09-08 |
ノバルティス アーゲー |
合成アペリンポリペプチドのバイオコンジュゲート
|
|
AU2014293386B2
(en)
|
2013-07-25 |
2016-11-17 |
Novartis Ag |
Cyclic polypeptides for the treatment of heart failure
|
|
IN2013MU02470A
(cg-RX-API-DMAC10.html)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
|
US10112898B2
(en)
|
2013-09-06 |
2018-10-30 |
Cadila Healthcare Limited |
Process for the preparation of saroglitazar pharmaceutical salts
|
|
CR20160207A
(es)
|
2013-11-05 |
2016-08-10 |
Ben Gurion Univ Of The Negev Res And Dev Authority |
Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad
|
|
CN103641761A
(zh)
*
|
2013-11-22 |
2014-03-19 |
沈阳化工大学 |
一种维格利汀的制备方法
|
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
|
EA201691793A1
(ru)
|
2014-03-06 |
2016-12-30 |
Сановель Илач Санайи Ве Тиджарет А.Ш. |
Способ получения состава на основе вилдаглиптина в атмосфере инертного газа
|
|
CN103992257B
(zh)
*
|
2014-05-16 |
2016-03-30 |
苏州天马精细化学品股份有限公司 |
一种维格列汀粗品的纯化方法
|
|
CN105439873A
(zh)
*
|
2014-08-20 |
2016-03-30 |
天津药物研究院 |
3-羟基-1-金刚烷胺的制备方法
|
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
|
CN105884669B
(zh)
*
|
2014-09-15 |
2020-05-15 |
深圳翰宇药业股份有限公司 |
制备取代的(s)-吡咯烷-2-甲腈及维格列汀的方法
|
|
EP4445956A3
(en)
|
2015-01-06 |
2024-12-04 |
Arena Pharmaceuticals, Inc. |
Compound for use in treating conditions related to the s1p1 receptor
|
|
CN104529857B
(zh)
*
|
2015-01-13 |
2016-03-30 |
佛山市赛维斯医药科技有限公司 |
卤代金刚烷酰胺类衍生物、其制备方法和用途
|
|
BR112017014194A2
(pt)
|
2015-01-23 |
2018-01-09 |
Novartis Ag |
conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
|
|
KR20220070057A
(ko)
|
2015-03-09 |
2022-05-27 |
인테크린 테라퓨틱스, 아이엔씨. |
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
|
|
CN104761456B
(zh)
*
|
2015-03-10 |
2020-04-10 |
上海威智医药科技有限公司 |
3-氨基-1-金刚烷醇的制备方法
|
|
CN104817482B
(zh)
*
|
2015-03-17 |
2017-05-10 |
宁波百思佳医药科技有限公司 |
2‑取代吡咯烷类化合物、制备方法及其在制备维格列汀中的应用
|
|
PL3310760T3
(pl)
|
2015-06-22 |
2023-03-06 |
Arena Pharmaceuticals, Inc. |
Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
|
|
US10385017B2
(en)
|
2015-10-14 |
2019-08-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
|
RU2628573C2
(ru)
*
|
2015-11-27 |
2017-08-21 |
Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" |
Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа
|
|
MX2018007681A
(es)
|
2015-12-28 |
2018-11-14 |
Wockhardt Ltd |
Composicion farmaceutica osmotica oral de vildagliptin.
|
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
|
DE102016116130A1
(de)
|
2016-08-30 |
2018-03-01 |
Universität Bielefeld |
Verfahren zur Herstellung chiraler Aminonitrile
|
|
PL3512505T3
(pl)
|
2016-09-16 |
2023-08-07 |
Galenicum Health S.L.U. |
Farmaceutyczne kompozycje wildagliptyny
|
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
|
MX382765B
(es)
|
2016-12-09 |
2025-03-13 |
Zydus Lifesciences Ltd |
Tratamiento para la colangitis biliar primaria.
|
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
|
EP3606527A1
(en)
|
2017-04-03 |
2020-02-12 |
Coherus Biosciences, Inc. |
Ppar-gamma agonist for treatment of progressive supranuclear palsy
|
|
GR1009406B
(el)
|
2017-10-03 |
2018-11-26 |
Φαρματεν Αβεε |
Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μεθοδος για την παρασκευη αυτου
|
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
|
KR102622198B1
(ko)
|
2018-03-30 |
2024-01-09 |
한미약품 주식회사 |
빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
|
|
CA3102136A1
(en)
|
2018-06-06 |
2019-12-12 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
|
GR1009644B
(el)
|
2018-09-25 |
2019-11-12 |
Φαρματεν Α.Β.Ε.Ε. |
Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
|
|
WO2020110008A1
(en)
|
2018-11-27 |
2020-06-04 |
Novartis Ag |
Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
|
|
UY38485A
(es)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
|
|
EP3887388A1
(en)
|
2018-11-27 |
2021-10-06 |
Novartis AG |
Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
|
|
JP7461735B2
(ja)
*
|
2019-12-02 |
2024-04-04 |
日本ジェネリック株式会社 |
ビルダグリプチン含有錠剤
|
|
CN113527167B
(zh)
*
|
2020-04-14 |
2024-01-19 |
威智医药股份有限公司 |
一种维格列汀的生产方法
|
|
WO2021234430A1
(en)
|
2020-05-17 |
2021-11-25 |
Lotus International Pte. Ltd. |
Modified release dosage form comprising vildagliptin and process for manufacturing the same
|
|
WO2022003405A1
(en)
|
2020-07-03 |
2022-01-06 |
Savoi Guilherme |
One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same
|
|
EP4192509A1
(en)
|
2020-08-05 |
2023-06-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
|
JP2024504328A
(ja)
*
|
2021-01-21 |
2024-01-31 |
ザ スクリプス リサーチ インスティテュート |
肺疾患の治療のための肺胞２型細胞増殖の小分子調節因子
|
|
TW202333563A
(zh)
|
2021-11-12 |
2023-09-01 |
瑞士商諾華公司 |
用於治療疾病或障礙之二胺基環戊基吡啶衍生物
|
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|
|
CN121219288A
(zh)
|
2023-05-24 |
2025-12-26 |
诺华股份有限公司 |
用于治疗疾病或障碍的萘啶酮衍生物
|